First inhaled COPD treatment FDA approval in more than 20 years

Verona Pharma plc has announced the FDA approval of Ohtuvayre. This is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years.

According to David Zaccardelli, Pharm. D., President and Chief Executive Officer of Verona Pharma “The approval of Ohtuvayre is a significant advance in COPD care, and we believe Ohtuvayre’s novel profile can change the treatment paradigm for COPD. We plan to launch Ohtuvayre in the third quarter 2024, ensuring Ohtuvayre is available to help the millions of patients who still experience daily COPD symptoms.”

Click here to read the entire article.